已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Corticosteroids versus clobazam for treatment of children with epileptic encephalopathy with spike-wave activation in sleep (RESCUE ESES): a multicentre randomised controlled trial

克洛巴扎姆 医学 儿科 随机对照试验 奥卡西平 不利影响 麻醉 人口 癫痫 精神科 内科学 卡马西平 环境卫生
作者
Marleen M L van Arnhem,Bart van den Munckhof,Alexis Arzimanoglou,Emilio Perucca,Liisa Metsähonkala,Guido Rubboli,Marianne Søndergaard Khinchi,Anne de Saint Martin,Kerstin Alexandra Klotz,Julia Jacobs,J. Helen Cross,Irene Morales,Wim Otte,Heleen C. van Teeseling,Frans S.S. Leijten,Kees P. J. Braun,Floor E. Jansen,Anna Jansen,Lieven Lagae,Thomas Bast
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:23 (2): 147-156 被引量:8
标识
DOI:10.1016/s1474-4422(23)00409-x
摘要

Background Epileptic encephalopathy with spike-wave activation in sleep (EE-SWAS) is a rare syndrome associated with cognitive and behavioural regression. On the basis of mostly small observational and retrospective studies, corticosteroids and clobazam are often considered the most effective treatments for this syndrome. We aimed to compare cognitive outcomes of children with EE-SWAS 6 months after starting treatment with either corticosteroids or clobazam. Methods We did a multicentre, randomised controlled trial at eight tertiary referral centres for rare epilepsies in seven European countries. Children were eligible to participate if they were aged 2–12 years, were diagnosed with EE-SWAS within 6 months before inclusion, and had not been treated with corticosteroids or clobazam previously. Participants were randomly assigned (1:1) to treatment with corticosteroids (either continuous treatment with 1–2 mg/kg per day of prednisolone orally or pulse treatment with 20 mg/kg per day of methylprednisolone intravenously for 3 days every 4 weeks) or clobazam (0·5–1·2 mg/kg per day orally). The primary outcome was cognitive functioning after 6 months of treatment, which was assessed by either the intelligence quotient (IQ) responder rate (defined as improvement of ≥11·25 IQ points) or the cognitive sum score responder rate (defined as improvement of ≥0·75 points). Safety was assessed by number of adverse events and serious adverse events. Data were analysed in the intention-to-treat population, which included all children as randomised who had primary outcome data available at 6 months. The trial is registered with the Dutch Trial Register, Toetsingonline, NL43510.041.13, and the ISRCTN registry, ISRCTN42686094. The trial was terminated prematurely because enrolment of the predefined number of 130 participants was deemed not feasible. Findings Between July 22, 2014, and Sept 3, 2022, 45 children were randomly assigned to either corticosteroids (n=22) or clobazam (n=23); two children assigned clobazam dropped out before 6 months and were excluded from the intention-to-treat analysis. At the 6-month assessment, an improvement of 11·25 IQ points or greater was reported for five (25%) of 20 children assigned corticosteroids versus zero (0%) of 18 assigned clobazam (risk ratio [RR] 10·0, 95% CI 1·2–1310·4; p=0·025). An improvement of 0·75 points or more in the cognitive sum score was recorded for one (5%) of 22 children assigned corticosteroids versus one (5%) of 21 children assigned clobazam (RR 1·0, 95% CI 0·1–11·7, p=0·97). Adverse events occurred in ten (45%) of 22 children who received corticosteroids, most frequently weight gain, and in 11 (52%) of 21 children who received clobazam, most often fatigue and behavioural disturbances. Occurrence of adverse events did not differ between groups (RR 0·8, 95% CI 0·4–1·4; p=0·65). Serious adverse events occurred in one child in the corticosteroid group (hospitalisation due to laryngitis) and in two children in the clobazam group (hospitalisation due to seizure aggravation, and respiratory tract infection). No deaths were reported. Interpretation The trial was terminated prematurely, and the target sample size was not met, so our findings must be interpreted with caution. Our data indicated an improvement in IQ outcomes with corticosteroids compared with clobazam treatment, but no difference was seen in cognitive sum score. Our findings strengthen those from previous uncontrolled studies that support the early use of corticosteroids for children with EE-SWAS. Funding EpilepsieNL, WKZ fund, European Clinical Research Infrastructure Network, and Ming fund.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
古道小七完成签到,获得积分10
1秒前
Ramer556发布了新的文献求助10
2秒前
pumpkin发布了新的文献求助10
3秒前
领导范儿应助温柔烧鹅采纳,获得10
11秒前
LJC完成签到,获得积分10
12秒前
Ramer556完成签到,获得积分10
14秒前
14秒前
14秒前
负责怀莲发布了新的文献求助10
15秒前
夏夏完成签到 ,获得积分10
20秒前
20秒前
bkagyin应助hhllhh采纳,获得10
27秒前
顾矜应助魁梧的人达采纳,获得10
28秒前
Ava应助mw采纳,获得10
30秒前
31秒前
32秒前
所所应助zephyr采纳,获得30
33秒前
负责怀莲发布了新的文献求助10
34秒前
34秒前
儒雅南风发布了新的文献求助10
35秒前
35秒前
35秒前
37秒前
hhllhh发布了新的文献求助10
38秒前
38秒前
39秒前
40秒前
奥特超曼应助123采纳,获得10
40秒前
42秒前
Iris发布了新的文献求助10
42秒前
漂亮白枫发布了新的文献求助10
43秒前
trf完成签到,获得积分10
45秒前
李健应助负责怀莲采纳,获得10
45秒前
思源应助无情的宛儿采纳,获得10
47秒前
49秒前
55秒前
yuan关注了科研通微信公众号
56秒前
隐形曼青应助hhllhh采纳,获得10
59秒前
所所应助Ray采纳,获得10
1分钟前
PMoLGGYM2021发布了新的文献求助10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Aktuelle Entwicklungen in der linguistischen Forschung 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989868
求助须知:如何正确求助?哪些是违规求助? 3531994
关于积分的说明 11255752
捐赠科研通 3270793
什么是DOI,文献DOI怎么找? 1805053
邀请新用户注册赠送积分活动 882215
科研通“疑难数据库(出版商)”最低求助积分说明 809208